Reata Pharmaceuticals, Inc. to Report Third Quarter 2021 Financial Results and to Provide an Update on Development Programs on November 8, 2021
Reata’s management will host a conference call on
Third quarter financial results to be discussed during the call will be included in an earnings press release that will be available on the Company’s website shortly before the call at http://reatapharma.com/investors/ and will be available for 12 months after the call. The audio recording and webcast will be accessible for at least 90 days after the event at http://reatapharma.com/investors/.
About
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005543/en/
(972) 865-2219
http://reatapharma.com
Investors:
ir@reatapharma.com
media@reatapharma.com
https://www.reatapharma.com/contact-us/
Source:
